KHKonstanze Hörtnagel

Konstanze Hörtnagel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Konstanze Hörtnagel has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Malta (MYH9 Associated Elastin Aggregation) Syndrome: Germline Variants in MYH9 Cause Rare Sweat Duct Proliferations and Irregular Elastin Aggregations

    by Eleanor Fewings, Mirjana Ziemer, Konstanze Hörtnagel, Kerstin Reicherter, Alexey Larionov, James Redman, Mae A. Goldgraben, Alexander Pepler, Tim Hearn, Helen Firth, et al.


  • Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment

    by Claudia B. Catarino, Christian Vollmar, Clemens Küpper, Klaus Seelos, Constanze Gallenmüller, Joanna Bartkiewicz, Saskia Biskup, Konstanze Hörtnagel, Thomas Klopstock

    Cerebrotendinous xanthomatosis (CTX, MIM 213700) is a rare autosomal recessive lipid storage disorder caused by CYP27A1 mutations. Treatment with chenodeoxycholic acid (CDCA) may slow the progression of the disease and reverse some symptoms in a proportion of patients. In a non-consanguineous Caucasian family, two siblings with CTX were evaluated before treatment and prospectively followed-up every 6 months after starting CDCA therapy, using systematic clinical examination, neuropsychological tests, laboratory tests, electroencephalography (EEG) and brain MRI, diffusion tensor imaging (DTI) and tractography. A 30-year-old patient and her 27-year-old brother were referred for progressive spastic paraparesis. Both had epilepsy, learning difficulties, chronic diarrhoea and juvenile-onset cataracts. CTX was diagnosed by increased cholestanol levels and compound heterozygosity for CYP27A1 mutations. Therapy with CDCA led to resolution of chronic diarrhoea, normalisation of serum cholestanol and EEG, and a progressive improvement in gait, cognition and seizure control. Before treatment, conventional brain MRI showed no CTX-related abnormalities for the proband and no cerebellar abnormalities for the brother, while DTI showed reduced fractional anisotropy (FA) and tract-density in the cerebellum and widespread cerebral reductions of FA in both patients, compared to a group of 35 healthy controls. Repeated DTI after starting therapy showed progressive increases of cerebellar tract density and of cerebral FA. In patients with CTX, therapy with CDCA may lead to significant clinical improvement, with normalisation of biochemical and electrophysiological biomarkers. DTI and tractography may detect changes when the conventional MRI is unremarkable and may provide potential neuroimaging biomarkers for monitoring treatment response in CTX, while the conventional MRI remains unchanged.


  • Dropped Head Syndrom als Folge einer behandelbaren metabolischen Myopathie

    by Bertold Schrank, Harald von Pein, Clemens Sommer, Dorothea Haas, Konstanze Hörtnagel, Saskia Biskup

    Wir berichten über den ungewöhnlichen Fall einer metabolischen Myopathie, die sich mit einem Dropped Head Syndrom (DHS) mit myographischen und bildgebenden Veränderungen vereinbar mit einer fokalen inflammatorischen Myopathie erstmanifestierte. Der Fall zeigt, dass die gezielte Biopsie auch schwerer zugänglicher Muskeln entscheidend sein kann zur korrekten Diagnose.